Peptron Past Earnings Performance
Past criteria checks 0/6
Peptron's earnings have been declining at an average annual rate of -9.3%, while the Life Sciences industry saw earnings growing at 21.9% annually. Revenues have been growing at an average rate of 12.8% per year.
Key information
-9.3%
Earnings growth rate
-1.9%
EPS growth rate
| Life Sciences Industry Growth | 53.7% |
| Revenue growth rate | 12.8% |
| Return on equity | -44.1% |
| Net Margin | -476.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Peptron makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 3,342 | -15,922 | 5,213 | 11,444 |
| 30 Sep 23 | 3,335 | -18,977 | 5,203 | 13,602 |
| 30 Jun 23 | 3,880 | -17,881 | 5,360 | 13,186 |
| 31 Mar 23 | 4,194 | -17,045 | 5,116 | 13,197 |
| 31 Dec 22 | 5,814 | -15,063 | 4,861 | 13,367 |
| 30 Sep 22 | 5,811 | -12,735 | 4,840 | 12,389 |
| 30 Jun 22 | 5,414 | -13,971 | 4,878 | 12,813 |
| 31 Mar 22 | 8,598 | -11,884 | 5,021 | 13,563 |
| 31 Dec 21 | 6,625 | -15,042 | 5,004 | 14,842 |
| 30 Sep 21 | 6,656 | -15,929 | 4,929 | 15,777 |
| 30 Jun 21 | 6,748 | -15,962 | 4,737 | 16,105 |
| 31 Mar 21 | 3,439 | -19,908 | 4,542 | 15,619 |
| 31 Dec 20 | 3,121 | -18,382 | 4,191 | 14,180 |
| 30 Sep 20 | 2,744 | -23,456 | 3,763 | 12,580 |
| 30 Jun 20 | 2,215 | -22,821 | 3,556 | 12,058 |
| 31 Mar 20 | 1,683 | -19,222 | 3,303 | 10,992 |
| 31 Dec 19 | 1,801 | -17,718 | 3,241 | 9,835 |
| 30 Sep 19 | 2,319 | -8,422 | 3,425 | 8,747 |
| 30 Jun 19 | 2,806 | -7,235 | 3,288 | 7,651 |
| 31 Mar 19 | 3,255 | -4,314 | 3,218 | 6,568 |
| 31 Dec 18 | 3,862 | -3,726 | 3,074 | 6,069 |
| 30 Sep 18 | 4,383 | -4,201 | 2,750 | 5,800 |
| 30 Jun 18 | 4,142 | -2,575 | 2,399 | 4,765 |
| 31 Mar 18 | 3,915 | -4,760 | 2,143 | 4,205 |
| 31 Dec 17 | 3,215 | -4,427 | 2,064 | 3,737 |
| 30 Sep 17 | 2,587 | -4,164 | 2,076 | 3,373 |
| 30 Jun 17 | 2,761 | -4,043 | 2,005 | 3,143 |
| 31 Mar 17 | 2,951 | -3,607 | 1,912 | 3,030 |
| 31 Dec 16 | 3,131 | -3,191 | 1,875 | 2,771 |
| 30 Sep 16 | 2,930 | -3,080 | 1,669 | 2,374 |
| 30 Jun 16 | 3,028 | -3,065 | 1,793 | 2,343 |
| 31 Mar 16 | 2,691 | -3,057 | 1,707 | 2,110 |
| 31 Dec 15 | 2,812 | -2,734 | 1,606 | 2,006 |
| 30 Sep 15 | 2,571 | -2,617 | 1,686 | 1,842 |
| 30 Jun 15 | 2,565 | -2,621 | 1,500 | 2,037 |
| 31 Mar 15 | 2,874 | -2,636 | 1,570 | 2,026 |
| 31 Dec 14 | 2,484 | -3,046 | 1,608 | 1,991 |
| 31 Dec 13 | 3,103 | -2,059 | 1,186 | 1,918 |
Quality Earnings: A087010 is currently unprofitable.
Growing Profit Margin: A087010 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A087010 is unprofitable, and losses have increased over the past 5 years at a rate of 9.3% per year.
Accelerating Growth: Unable to compare A087010's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A087010 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (8.1%).
Return on Equity
High ROE: A087010 has a negative Return on Equity (-44.07%), as it is currently unprofitable.